RUNX2 and osteosarcoma: Studies have demonstrated that RUNX2 could alleviate high glucose‐suppressed osteogenic differentiation via the Wnt/β‐catenin pathway and it has also been discovered that RUNX2 could control osteosarcoma apoptosis via the Wnt/β‐catenin signaling pathway.46, 47